This content is machine translated Multiple sclerosis Avoiding the nocebo trap with natalizumab biosimilars Monoclonal antibodies such as natalizumab are indispensable for multiple sclerosis therapy. A first recently approved biosimilar is clinically equivalent, as studies have shown. Nevertheless, reservations are widespread in practice. Patients...…
View Post 6 min This content is machine translated Therapy of non-scarring alopecias Less in summer, more in winter In a broad overview of non-scarring alopecias, Prof. Ralph M. Trüeb, MD, Wallisellen, Switzerland, addressed the successes of previous therapies and discussed the current evidence base at the 96th Annual…
